title: Effects of blockade of fatty acid oxidation on whole body and tissue-specific glucose metabolism in rats.
abstract: We examined the effect of the long-chain fatty acid oxidation blocker methyl palmoxirate (methyl 2-tetradecyloxiranecarboxylate, McN-3716) on glucose metabolism in conscious rats. Fasted animals [5 h with or without hyperinsulinemia (100 mU/l) and 24 h] received methyl palmoxirate (30 or 100 mg/kg body wt po) or vehicle 30 min before a euglycemic glucose clamp. Whole body and tissue-specific glucose metabolism were calculated from 2-deoxy-[3H]-glucose kinetics and accumulation. Oxidative metabolism was assessed by respiratory gas exchange in 24-h fasted animals. Pyruvate dehydrogenase complex activation was determined in selected tissues. Methyl palmoxirate suppressed whole body lipid oxidation by 40-50% in 24-h fasted animals, whereas carbohydrate oxidation was stimulated 8- to 10-fold. Whole body glucose utilization was not significantly affected by methyl palmoxirate under any conditions; hepatic glucose output was suppressed only in the predominantly gluconeogenic 24-h fasted animals. Methyl palmoxirate stimulated glucose uptake in heart in 24-h fasted animals [15 +/- 5 vs. 220 +/- 28 (SE) mumol x 100 g-1 x min-1], with smaller effects in 5-h fasted animals with or without hyperinsulinemia. Methyl palmoxirate induced significant activation of pyruvate dehydrogenase in heart in the basal state, but not during hyperinsulinemia. In skeletal muscles, methyl palmoxirate suppressed glucose utilization in the basal state but had no effect during hyperinsulinemia; pyruvate dehydrogenase activation in skeletal muscle was not affected by methyl palmoxirate under any conditions. The responses in skeletal muscle are consistent with the operation of a mechanism similar to the Pasteur effect.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia.
authors.forename: A B
authors.initials: AB
authors.lastname: Jenkins
authors.forename: L H
authors.initials: LH
authors.lastname: Storlien
authors.forename: G J
authors.initials: GJ
authors.lastname: Cooney
authors.forename: G S
authors.initials: GS
authors.lastname: Denyer
authors.forename: I D
authors.initials: ID
authors.lastname: Caterson
authors.forename: E W
authors.initials: EW
authors.lastname: Kraegen
mesh_terms: D000818:Animals; D001769:Blood / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004852:Epoxy Compounds / Q000493:pharmacokinetics / Q000494:pharmacology; D005215:Fasting; D005227:Fatty Acids / Q000037:antagonists & inhibitors*; D005947:Glucose / Q000378:metabolism*; D008297:Male; D010084:Oxidation-Reduction / Q000187:drug effects; D011422:Propionates / Q000493:pharmacokinetics / Q000494:pharmacology; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011768:Pyruvate Dehydrogenase Complex / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D004852:Epoxy Compounds; D005227:Fatty Acids; D011422:Propionates; D011768:Pyruvate Dehydrogenase Complex; D005947:Glucose; C017522:methyl 2-tetradecylglycidate